Kniep, Helge
Meyer, Lukas
Broocks, Gabriel
Bechstein, Matthias
Guerreiro, Helena
Winkelmeier, Laurens
Brekenfeld, Caspar
Flottmann, Fabian
Deb-Chatterji, Milani
Alegiani, Anna
Hanning, Uta
Thomalla, Götz
Fiehler, Jens
Gellißen, Susanne
,
Röther, Joachim
Eckert, Bernd
Braun, Michael
Hamann, Gerhard F.
Siebert, Eberhard
Nolte, Christian
Zweynert, Sarah
Bohner, Georg
Berrouschot, Jörg
Bormann, Albrecht
Kraemer, Christoffer
Leischner, Hannes
Hattingen, Jörg
Petersen, Martina
Stögbauer, Florian
Boeckh-Behrens,
Wunderlich, Silke
Ludolph, Alexander
Henn, Karl-Heinz
Gerloff, Christian
Fiehler, Jens
Thomalla, Götz
Alegiani, Anna
Schell, Maximilian
Reich, Arno
Nikoubashman, Omid
Dorn, Franziska
Petzold, Gabor
Liman, Jan
Schäfer, Jan Hendrik
Keil, Fee
Gröschel, Klaus
Uphaus, Timo
Schellinger, Peter
Borggrefe, Jan
Tiedt, Steffen
Kellert, Lars
Trumm, Christoph
Ernemann, Ulrike
Poli, Sven
Riedel, Christian
Ernst, Marielle Sophie
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 18 February 2023
Accepted: 17 October 2023
First Online: 31 October 2023
Competing interests
: Helge Kniep and Fabian Flottmann are consultants for Eppdata GmbH. Helge Kniep is shareholder of Eppdata GmbH. Milani Deb-Chatterji has received research grants from the Werner Otto Stiftung and serves in the advisory board of the PRECIOUS Trial. Götz Thomalla received fees as consultant from Acandis, Boehringer Ingelheim, Bayer, and Portola, and fees as lecturer from Acandis, Alexion, Amarin, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichii Sankyo and Portola. He serves in the board of the TEA Stroke Study and of ESO. Jens Fiehler is consultant for Cerenovus, Medtronic, Microvention, Penumbra, Phenox, Roche and Tonbridge. He serves in the advisory board of Stryker and Phenox. He is stock holder of Tegus Medical, Eppdata and Vastrax. He serves as Associate Editor at JNIS. All other authors have nothing to declare.